Frontline Rituximab Plus Bendamustine in Waldenström Macroglobulinemia
Outcome data from 222 patients with active Waldenstrom macroglobulinemia who were treated at the Mayo Clinic over 18 years were retrospectively reviewed.
Outcome data from 222 patients with active Waldenstrom macroglobulinemia who were treated at the Mayo Clinic over 18 years were retrospectively reviewed.
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
Researchers developed a new model for risk stratification in patients with SMM based on updated criteria.
Researchers sought to expand upon what is known about smoking status and AML diagnosis and understand more about how smoking affects treatment outcomes.
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
The U.S. Food and Drug Administration has approved brentuximab vedotin for the treatment of adult patients with pcALCL or CD30-expressing mycosis fungoides who have received prior systemic therapy.